ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Approves Therapy for Disease that Causes Low Phosphate Blood Levels, Bone Softening
June 30, 2020The U.S. Food and Drug Administration (FDA) has approved Crysvita (burosumab-twza) injection to treat patients age two and older with tumor-induced osteomalacia (TIO). -
US FDA grants approval to Ultragenyx Pharmaceutical for Crysvita
June 22, 2020The drug has been approved to treat patients with tumor-induced osteomalacia (TIO), a rare disease that is characterized by the development of tumors that cause weakened and softened bones.
Pharma Sources Insight January 2025
